Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Real-time Estimate Cboe BZX Other stock markets 10:23:34 2026-05-21 am EDT			5-day change	1st Jan Change
11.96 ^USD	-2.41%		-8.40%	+33.37%

May. 12	Intellia Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03:40 PM
May. 11	Intellia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Transcript : Intellia Therapeutics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-14-2026 09

Published on 01/14/2026 at 01:35 pm EST - Modified on 01/14/2026 at 02:05 pm EST

S&P Capital IQ

Presenter Speech
Lut Ming Cheng (Analysts)

Good morning. Thanks for joining us for another session at the 44th JPMorgan Healthcare Conference. I'm Brian Cheng, one of the senior biotech analysts here

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Intellia Therapeutics, Inc.

May. 12	Intellia Therapeutics, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 03:40 PM
May. 11	Intellia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 11	Intellia Therapeutics Q1 Loss Narrows, Revenue Falls	MT
May. 11	Earnings Flash (NTLA) Intellia Therapeutics Posts Q1 Net Loss $0.81 a Share, vs. FactSet Est of $0.91 Loss	MT
May. 11	Earnings Flash (NTLA) Intellia Therapeutics, Inc. Reports Q1 Revenue $15.0M, vs. FactSet Est of $13.8M	MT
Apr. 28	Chardan Lifts Price Target on Intellia Therapeutics to $30 From $27, Keeps Buy Rating	MT
Apr. 27	Intellia Therapeutics Launches $150 Million Stock Offering	MT
Apr. 27	Intellia Therapeutics, Inc. has filed an IPO.	CI
Apr. 27	Intellia Therapeutics, Inc. - Special Call
Apr. 27	Intellia Therapeutics Starts Rolling FDA Application After Phase 3 Angioedema Trial Meets Primary Endpoint	MT
Apr. 27	Intellia's gene therapy for rare disease cuts swelling attacks in late-stage trial	RE
Apr. 27	Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to Fda for Lonvoguran Ziclumeran as A One-Time Treatment for Hereditary Angioedema	CI
Apr. 27	Intellia Therapeutics Reports Positive Phase 3 Results In Hereditary Angioedema	CI
Mar. 06	Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
Mar. 03	Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran	CI